BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 31391376)

  • 1. [Precision medicine for acute myeloid leukemia based on genomic profiling].
    Sanada M
    Rinsho Ketsueki; 2019; 60(7):847-853. PubMed ID: 31391376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
    DiNardo C; Lachowiez C
    Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.
    Hirsch P; Tang R; Abermil N; Flandrin P; Moatti H; Favale F; Suner L; Lorre F; Marzac C; Fava F; Mamez AC; Lapusan S; Isnard F; Mohty M; Legrand O; Douay L; Bilhou-Nabera C; Delhommeau F
    Haematologica; 2017 Jul; 102(7):1227-1237. PubMed ID: 28302711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
    Yang F; Anekpuritanang T; Press RD
    Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision medicine in acute myeloid leukemia: Hope, hype or both?
    Prasad V; Gale RP
    Leuk Res; 2016 Sep; 48():73-7. PubMed ID: 27497757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia.
    Richardson DR; Foster MC; Coombs CC; Zeidner JF
    Semin Oncol Nurs; 2019 Dec; 35(6):150957. PubMed ID: 31759819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
    Ehinger M; Pettersson L
    APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.
    Selim AG; Moore AS
    J Mol Diagn; 2018 Jul; 20(4):389-397. PubMed ID: 29689379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mind map for managing minimal residual disease in acute myeloid leukemia.
    Benton CB; Ravandi F
    Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introducing minimal residual disease in acute myeloid leukemia.
    Ofran Y; Rowe JM
    Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of molecular MRD monitoring by next-generation sequencing in patients with
    Shumilov E; Flach J; Joncourt R; Porret N; Wiedemann G; Novak U; Gfeller E; Jeker B; Amstutz U; Pabst T; Bacher U
    Leuk Lymphoma; 2019 Oct; 60(10):2588-2590. PubMed ID: 30998101
    [No Abstract]   [Full Text] [Related]  

  • 13. Minimal Residual Disease in Acute Myeloid Leukemia.
    Sung PJ; Luger SM
    Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
    N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice?
    Luskin MR; Stone RM
    J Oncol Pract; 2017 Aug; 13(8):471-480. PubMed ID: 28796964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia].
    Ishikawa Y
    Rinsho Ketsueki; 2018; 59(10):1997-2006. PubMed ID: 30305502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.
    Mencia-Trinchant N; Hu Y; Alas MA; Ali F; Wouters BJ; Lee S; Ritchie EK; Desai P; Guzman ML; Roboz GJ; Hassane DC
    J Mol Diagn; 2017 Jul; 19(4):537-548. PubMed ID: 28525762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.